Clinical Trials
35 trialsNCT06955169 2026-05-22
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Suspended
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07033598 2026-03-05
PROSPERA
Theradex
Phase 2 Recruiting
NCT05020652 2025-12-17
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Active not recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT03944915 2025-05-11
DEPEND
University of Chicago
Phase 2 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT05005182 2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Phase 2 Terminated
NCT02626715 2024-07-16
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
Phase 2 Completed
NCT01693718 2024-01-29
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
University of Chicago
Phase 2 Completed
NCT02088541 2023-01-26
SOPRA
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT00006119 2021-02-21
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
UNICANCER
Phase 2 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT00468169 2019-10-09
EPIC
University of Chicago
Phase 2 Completed
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT00019474 2018-09-14
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Montefiore Medical Center
Phase 2 Completed
NCT00462735 2018-03-13
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT00978146 2017-04-20
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Children's Hospital of Philadelphia
Phase 2 Withdrawn
NCT00706810 2017-04-13
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
Phase 2 Completed
NCT00003590 2016-05-20
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
SWOG Cancer Research Network
Phase 2 Completed
NCT00004094 2014-01-06
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002951 2013-09-05
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
University of Chicago
Phase 2 Completed
NCT00904735 2013-08-12
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00083187 2013-07-18
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004089 2013-07-10
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003172 2013-06-21
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00615927 2013-03-15
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Phase 2 Completed
NCT00354913 2013-01-18
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Phase 2 Completed
NCT00002940 2012-10-19
Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00004897 2012-06-12
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Northwestern University
Phase 2 Terminated
NCT00290771 2011-05-16
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated
NCT00002674 2010-04-02
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed